Inhibition of SREBP-1 expression can suppress glucose metabolism in HCC cells, resulting in a synergistic anti-tumor effect combined with immunotherapy with Sorafenib on HCC in vivo [81]. Here, SREBF1 is linked to hepatocellular carcinoma.